As the number of approved cell and gene therapies continues to grow, and awareness among the public of their therapeutic capabilities becomes more widespread, it is more pressing than ever to address the challenges of scalability and patient access to these life-improving medicines. Digitization and automation are critical tools in the manufacturing and delivery of cell and gene therapies, tackling issues in throughput, data management, safety and availability. In collaboration with the Cell and Gene Therapy Catapult, Autolomous has demonstrated the value of implementing digitization and data integration to an end-to-end AAV manufacturing process, yielding a saving of 100 QA FTE days in document review and release, a 92% reduction in error rate, and an eradication of time taken for team notification, controlled document retrieval and material and equipment traceability. As a result of this project, further opportunities have been identified in expanding the integrated instrument and system set, and implementation in a fully automated factory of the future setting. Through this poster presentation, Autolomous will discuss the key benefits resulting from the collaboration, and share our learnings for effective and efficient digital adoption in cell and gene therapy manufacturing to support the necessary scalability, and ultimately access to advanced therapies that patients need.